The Toronto Raptors point guard is known for grabbing game balls after teammates or coaches have big nights and after the win against the Rockets, he explains why he does that.
The Toronto Raptors point guard is known for grabbing game balls after teammates or coaches have big nights and after the win against the Rockets, he explains why he does that.
The "Catering Software Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Deployment and End user" report has been added to ResearchAndMarkets.com's offering.
The Enrollment Management Association (EMA), a nonprofit organization that provides professional support, advocacy, and strategic tools to K12 independent school enrollment offices, announced today the launch of its newest product, PROSPECT, a comprehensive, opt-in student and parent database available for licensing by accredited higher education institutions. PROSPECT offers information on more than 60,000 private day and boarding school students and their parents, allowing universities to identify and recruit students starting in the ninth grade.
Merck to Discontinue Development of MK-7110 for COVID-19
Analysts on average had expected earnings per share of $7.64, according to Refinitiv IBES data. BlackRock's assets under management grew to a record $9 trillion in the quarter, compared with $6.47 trillion a year earlier.
Full-year 2020 Adjusted EBITDA of $16.9 million compared to Adjusted EBITDA loss of $0.8 million in 2019 Full-year 2020 cash from operating activities improved $34.2 million compared to 2019 Full-year 2020 cannabis revenue increased 41% compared to 2019 Full-year cash expenses decreased 30% compared to 2019 PHOENIX, April 15, 2021 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (CSE: TILT) (OTCQB: TLLTF) a provider of business solutions to the global cannabis industry that includes inhalation technologies, cultivation, manufacturing, processing, brand development and retail, reported its financial and operating results for the three and twelve-months ended December 31, 2020. All financial information is provided in U.S. dollars except where otherwise indicated. Results of Yaris Acquisition, LLC and its subsidiaries (together, “Blackbird”) have been reclassified as discontinued operations on the income statement and statement of cash flows. All periods have been updated to reflect this change. “The primary focus in 2020 was for TILT to become profitable, putting in place the pieces necessary to achieve scale and engage in a steady and sustainable growth trajectory,” said Gary Santo, President of TILT. “We made a number of key decisions throughout the year that have already started to pay off, allowing the Company to have a strong finish to 2020, producing $16.9 million in Adjusted EBITDA and $16.7 million in cash from operating activities for the year. We look to carry that momentum into 2021 and are already off to a great start across all business units, supporting management’s previously announced full-year 2021 revenue guidance of $205 million to $210 million and Adjusted EBITDA guidance of $30 million to $32 million.” “TILT underwent significant changes in 2020,” added Mark Scatterday, CEO of TILT. “Through the tireless efforts of our team we were able to stabilize our foundation, solidify our strategy and focus on how best to deploy available resources towards our high-growth plant touching assets, allowing TILT to provide a differentiated B2B platform capable of supporting independent brands, U.S. MSOs and Canadian LPs. We expect 2021 to be an exciting year as we continue our transition from being a holding company possessing a disparate collection of subsidiaries to an integrated operating company capable of benefitting from economies of scale and cross-selling opportunities.” Financial Highlights from Continuing Operations for the Quarter Ended December 31, 2020 Revenue of $42.3 million, an 8.1% increase from the third quarter of 2020 and an increase of 35.4% from the prior year period.Gross margin before fair value adjustments of 26.7%, down 460 basis points (“bps”) from the third quarter of 2020 and up 200 bps from the prior year period. Operating expenses less non-cash adjustments for stock compensation, depreciation/ amortization and one-time charges was $8.3 million, flat compared to the third quarter and a 17.7% decline from the prior year period.Positive Adjusted EBITDA for the fourth consecutive quarter at $4.5 million.Cash and cash equivalents of $7.4 million, a $3.1 million increase from the previous quarter, due to robust cashflow from operations.Working Capital of $57.4 million, an $8.5 million increase from the previous quarter. Operational Highlights for the Quarter Ended December 31, 2020 Jupiter Research LLC’s (“Jupiter”) power supply revenue doubled from Q3 2020 to Q4 2020.Standard Farms, LLC (“Standard Farms”) posted record revenue for the quarter, including the two highest sales months in Company history.Standard Farms doubled extraction processing capacity during the quarter.Commonwealth Alternative Care, Inc.’s (“CAC”) lab and kitchen production capacity increased 100% during the quarter; cultivation expansion approved October 2020 planted during Q4 2020 and yielded first harvest in March 2021.Completed sale of Blackbird. Operational Highlights Subsequent to Quarter End Closed acquisition of Standard Farms Ohio LLC.Jupiter saw record cartridge shipments in January and record orders in February.Jupiter received ISO 13485:2016 Medical Device Certification.Launch of Her Highness NYC branded products in Massachusetts within 30 days of signing manufacturing and distribution contract.CAC completed planting in its eight additional grow rooms in Massachusetts during the quarter.Standard Farms had its highest flower sales during the month of March. Earnings Call and Webcast The Company will host a webcast at 8:00 AM EDT to discuss financial and operational results for the reported quarter. The live webcast may be accessed from the Events and Presentations menu in the Investor Relations section of the Company’s website at https://investors.tiltholdings.com/ir-calendar or to access the conference call via telephone, please dial, 1-877-705-6003. Please register at least 15 minutes prior to the scheduled start to download and install any necessary audio software. A replay of the webcast will be available in the Past Events section of the Company’s Investor Relations website approximately 2 hours after the live event and will be archived for 30 days. About TILT TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 35 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter, a wholly owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, CAC in Massachusetts, Standard Farms in Pennsylvania and Standard Farms Ohio, LLC. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com. Forward-Looking Information This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, expectations regarding 2021 revenue and Adjusted EBITDA guidance, the anticipated transition from a holding company to an integrated operating company capable of benefitting from economies of scale and cross-selling opportunities, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law. By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements. For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Management Discussion and Analysis of the Company for the quarter and year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com. Non-IFRS Financial and Performance Measures In addition to providing financial measurements based on International Financial Reporting Standards (“IFRS”), the Company provides additional financial metrics that are not prepared in accordance with IFRS. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These non-IFRS financial measures are EBITDA and Adjusted EBITDA. Management believes that these non-IFRS financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results. As there are no standardized methods of calculating these non-IFRS measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. EBITDA and Adjusted EBITDA EBITDA and Adjusted EBITDA are financial measures that are not defined under IFRS. The Company uses these non-IFRS financial measures, and believes they enhance an investor’s understanding of the Company’s financial and operating performance from period to period, because they exclude certain material non-cash items and certain other adjustments management believes are not reflective of the Company’s ongoing operations and performance. The Company calculates EBITDA as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance expense (income), plus depreciation and amortization expense. Adjusted EBITDA excludes certain one-time, non-cash or non-operating expenses, as determined by management, including stock compensation expense, business acquisition expense, debt issuance costs, severance, unrealized (gain) loss on changes in fair value of biological assets and fair value changes in biological assets included in inventory sold. Reconciliations of Non-IFRS Financial and Performance MeasuresAdjusted EBITDA is reconciled to Net Loss below as well as the section labelled “Reconciliation of Net Income (Loss) to Non-IFRS Measures” in the Management Discussion and Analysis of the Company for the quarter and year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com. Selected Financial Results Table 1: Income Statement:(in US$ thousands, unaudited) Three Months Ended Year Ended($ thousands)Dec 31, 2020 Sep 30, 2020 Dec 31, 2019 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018Revenue$42,265 $39,083 $31,225 $158,409 $146,935 $ 3,502 Cost of Goods Sold 30,985 26,846 23,517 111,738 106,236 3,360Gross Profit, Before FV Adj. 11,280 12,237 7,708 46,671 40,699 142Gross Margin %, Before FV Adj. 26.7% 31.3% 24.7% 29.5% 27.7% 4.1%Gain on FV of Bio. Assets 13,650 14,477 9,250 47,298 37,459 151FV of Bio. Assets in Inventory Sold -14,063 -7,870 -5,348 -35,014 -19,790 -Gross Profit, After FV Adj. 10,867 18,844 11,610 58,955 58,368 293 Gross Margin %, After FV Adj. 25.7% 48.2% 37.2% 37.2% 39.7% 8.4%Total Operating Expenses 49,703 14,453 38,613 93,552 170,354 56,582Income (Loss) from Continuing Operations -38,836 4,391 -27,003 -34,597 -111,985 (56,289)Total Other Income (Expense) -15,841 -2,476 -9,200 -22,552 -13,217 (493,782)Income Tax Expense (Recovery) -9,313 3,639 -4,582 -5,043 -3,275 48Net (Loss) from Continuing Operations -45,364 -1,724 -31,621 -52,107 -121,927 (550,119)Net (Loss) from discontinued operations, net of tax -46,783 -2,893 -1,050 -53,650 -11,447 -Net (Loss)$(92,147) $(4,617) $(32,671) $(105,757) $(133,374) $(550,119) EBITDA, Non-IFRS -49,612 9,673 -27,881 -29,032 -89,022 (551,621)Adjusted EBITDA, Non-IFRS$ 4,545 $ 5,063 $ 1,564 $ 16,924 $ (845) $ (22,634) Table 2: Reconciliation of Non-IFRS Measures:(in US$ thousands, unaudited) Three Months Ended Year Ended($ thousands)Dec 31, 2020 Sep 30, 2020 Dec 31, 2019 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018Net (Loss) from Continuing Operations$(45,364) $(1,724) $(31,621) $(52,107) $(121,927) $(550,119) Add (Deduct) Impact of: Interest (Income) (1,595) (767) (843) (3,835) (3,280) (2,199)Finance Expense 1,847 2,981 4,398 10,336 13,463 -Income Tax Expense (Recovery) (9,313) 3,639 (4,582) (5,043) (3,275) 48Depreciation and Amortization 4,813 5,544 4,767 21,617 25,997 649Total Adjustments (4,248) 11,397 3,740 23,075 32,905 (1,502) EBITDA (Non-IFRS)$(49,612) $ 9,673 $(27,881) $(29,032) $(89,022) $(551,621) Add (Deduct) Impact of: Stock Compensation Expense 817 1,456 2,914 4,200 75,628 28,967Business Acquisition Expense - - 1,020 - 2,440 4,047Debt Issuance Costs - - 540 - 209 -Severance - - 1,026 279 1,204 -Foreign Exchange (Gain) Loss - - - - (76) 107(Gain) Loss on Sale of Assets (32) 102 598 70 610 -Lease Restructuring Costs - - - 280 - -Legal Settlement 275 - - 275 - -Unrealized (Gain) Loss on Investment in Equity Security 23 301 - 337 - -Loss on Loan Receivable 16,416 - 4,689 16,416 4,689 -One time bad debt expense 2,169 - - 2,169 - -Impairment (Recovery) of Inventory - - - - (1,418) 1,418Derecognition and impairment loss 34,076 138 22,560 34,214 22,560 494,448Unrealized (Gain) on Changes in FV of Bio. Assets (13,650) (14,477) (9,250) (47,298) (37,459) -FV Changes in Bio. Assets Included in Inventory Sold 14,063 7,870 5,348 35,014 19,790 -Total Adjustments 54,157 (4,610) 29,445 45,956 88,177 528,987 Adjusted EBITDA (Non-IFRS)$ 4,545 $ 5,063 $ 1,564 $16,924 $ (845) $(22,634) Table 3: Condensed Consolidated Statements of Cash Flow:(in US$ thousands, unaudited) Year Ended Dec 31, 2020 Year Ended Dec 31, 2019Cash provided by (used in) operating activities - continuing operations 16,693 (17,551)Cash (used in) operating activities - discontinuing operations (7,040) (10,404)Net cash provided by (used in) operating activities 9,653 (27,955) Cash (used in) investing activities - continuing operations (2,578) (95,962)Cash provided by (used in) investing activities - discontinuing operations 58 (275)Net cash (used in) investing activities (2,520) (96,237) Cash (used in) provided by financing activities - continuing operations (2,275) 29,145 Cash (used in) provided by financing activities - discontinuing operations (638) (633)Net cash (used in) provided by financing activities (2,913) 28,512 Effect of foreign exchange on cash and cash equivalents 627 1,012 Net change in cash and cash equivalents 4,847 (94,667) Cash and cash equivalents, beginning of year 2,579 97,247 Cash and cash equivalents, end of year$ 7,427 $ 2,579 Table 4: Condensed Consolidated Statements of Financial Position (Select Items) (in US$ thousands, unaudited): ($ thousands)Dec 31, 2020 Dec 31, 2019 Cash and Cash Equivalents$7,427 $2,580 Biological Assets 11,201 8,580 Inventory 52,634 48,169 Total Current Assets 101,889 94,708 Property, Plant & Equipment, Net 66,795 80,576 Total Assets 429,604 545,903 Total Current Liabilities 44,488 50,365 Total Long-Term Liabilities 102,069 111,672 Total Shareholders’ Equity 283,047 383,866 Working Capital 57,401 44,343 The CSE has neither approved nor disapproved the contents of this news release. Investor Relations Contact:Taylor Allisoninvestors@tiltholdings.com Media Contact:Ellen MellodyEllen@mattio.com570-209-2947
Gannett Co., Inc. ("Gannett", the "Company") (NYSE: GCI) announced today that it will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to the opening of the New York Stock Exchange. Management will host a conference call on Friday, May 7, 2021 at 8:30 A.M. Eastern Time. A copy of the earnings release will be posted to the Investor Relations section of Gannett’s website, investors.gannett.com.
Merck and Ridgeback Biotherapeutics Update on Clinical Development Program for Molnupiravir, an Investigational Therapeutic for Treatment of COVID-19
U.S. Bancorp reports first quarter 2021 results
Tapestry, Inc. (NYSE: TPR), a leading New York-based house of modern luxury accessories and lifestyle brands, today announced the appointment of Todd Kahn as Chief Executive Officer and Brand President of Coach, effective immediately, following a comprehensive search. In this role, Mr. Kahn is responsible for all aspects of the brand globally, reporting to Joanne Crevoiserat, Chief Executive Officer of Tapestry, Inc. Mr. Kahn joined the Company in January 2008 and has held a number of leadership roles within the organization, most recently serving as Interim Chief Executive Officer and Brand President of Coach since July 2020.
STORE Capital Corporation (NYSE: STOR), an internally managed net-lease real estate investment trust (REIT) that invests in Single Tenant Operational Real Estate, today announced that its Board of Directors has appointed President and Chief Operating Officer Mary Fedewa to succeed Christopher Volk as Chief Executive Officer. Mr. Volk will become Executive Chair of the Board following Morton Fleischer’s transition to Chair Emeritus, and Catherine Rice will become Lead Independent Director. The leadership and Board transitions will be effective today, April 15, 2021.
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021. “We are excited to welcome Ms. Ruff and Ms. Oliger to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer and President. “They join at a critical point in Reata’s development having just submitted our first New Drug Application for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease caused by Alport syndrome. Both Ms. Ruff and Ms. Oliger bring a wealth of experience that will be invaluable in helping us achieve our mission to develop innovative therapies that change patients’ lives for the better.” Ms. Oliger brings nearly 30 years of experience in the biopharmaceutical industry, serving in various commercial roles at Genentech, Inc. and Roche Holding AG from January 2000 until her retirement in July 2020, and at Schering-Plough Corporation from September 1992 until December 1999. Most recently, Ms. Oliger served as Senior Vice President, Oncology Business Unit Head, at Genentech, Inc. During her tenure at Genentech, Inc., Ms. Oliger held senior leadership roles across a variety of therapeutic areas, including oncology, neurology, rare diseases, respiratory, dermatology, and immunology in hospital and specialty settings. She currently serves on the board of directors of Karyopharm Therapeutics Inc., a publicly traded pharmaceutical company. Ms. Oliger received a B.A. in Economics from the University of California at Santa Barbara. “I am pleased to be joining Reata’s Board of Directors at this pivotal moment,” said Ms. Oliger. “I look forward to working with Reata’s seasoned management team to prepare for the next stage in the Company’s growth and the commercial launch of bardoxolone in the United States and internationally, subject to regulatory review and approval.” Ms. Ruff brings over 30 years of experience in the biopharmaceutical industry, serving in various regulatory roles. Ms. Ruff has served as Chief Regulatory Affairs Officer and Senior Vice President, Head of Quality Assurance, at Stoke Therapeutics, Inc. since December 2018. From January 2013 to May 2018, Ms. Ruff served in various roles at Sarepta Therapeutics, Inc., including as Chief Regulatory Officer and Senior Vice President, Quality, from December 2015 to May 2018. Prior to her time at Sarepta Therapeutics, Inc., Ms. Ruff served in increasing senior regulatory roles at Sanofi, Amgen Inc., Abbott Laboratories, and AstraZeneca PLC. Ms. Ruff holds a bachelor’s degree in Chemistry and Biology from the University of Leicester, UK, and a master’s degree in Analytical Chemistry from the University of Loughborough, UK. Additionally, she is a Chartered Chemist and Member of the Royal Society of Chemistry. “I am delighted with the opportunity to join Reata’s Board of Directors,” said Ms. Ruff. “The results from the CARDINAL Phase 3 trial of bardoxolone in patients with chronic kidney disease caused by Alport syndrome as well as results from Part 2 of the MOXIe trial of omaveloxolone in patients with Friedreich’s ataxia highlight the potential of these novel therapies to treat patients affected by these deadly rare diseases. I’m thrilled with the opportunity to help advance these molecules through the next stages of development.” About Reata Pharmaceuticals, Inc. Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency. Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Contact:Reata Pharmaceuticals, Inc.(972) 865-2219https://www.reatapharma.com/ Investor Relations & Media:Manmeet Soni (469) 299-9130Andres Lorente (469) firstname.lastname@example.org@reatapharma.comhttps://www.reatapharma.com/contact-us/
Canada is facing industry calls to extend financial aid to smaller airlines, after offering a C$5.9 billion ($4.71 billion)life-line to Air Canada, as new COVID-19 variants cast early clouds ahead of the vital summer travel season. The timing of Monday's deal, which saw the Canadian government take a 6% equity stake in Air Canada, was partly designed to secure "access to air travel when it returns," as the country's vaccine rollout ramps up this summer, a source familiar with the discussions said. But with the spread of new variants threatening to overtake the pace of vaccination, early hopes for a relaxation of Canada's strict travel requirements ahead of summer are fading.
'Many in crypto believe the IPO will serve as a ‘stamp of approval’ for crypto as a whole,' one analyst said.
Global Hypersonic Technology Market to Reach $12. 92 Billion by 2031. Key Questions Answered in this Report: • What are the major drivers, challenges, and opportunities for the global hypersonic technology market during the forecast period 2021-2031?New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hypersonic Technology Market - A Global and Country Analysis: Focus on Type, End User, Launch Mode, and Country - Analysis and Forecast, 2021-2031" - https://www.reportlinker.com/p06061844/?utm_source=GNW • What are the recent trends in the hypersonic cruise missiles segment?• Who are the key players in the global hypersonic technology market, and what is their competitive benchmarking?• What is the expected revenue generated by the global hypersonic technology market during the forecast period 2021-2031?• What are the strategies adopted by the key players in the market to increase their market presence in the industry?• Which end-user (military and space) in the hypersonic technology market is expected to dominate the market in 2031?• What revenue are expected to be generated by the global hypersonic technology market (by launch mode) – surface to surface, surface to air, air to air and subsea to surface – in 2021, and what are the estimates till 2031?• What are the competitive strengths of the key players in the global hypersonic technology market?• What would be the aggravated revenue generated by the hypersonic technology market segmented by U.S., Russia, China, India, Australia, Japan, France, Germany and Rest-of-the-World.• What are the major restraints inhibiting the growth of the global hypersonic technology market?Global Hypersonic Technology Market Forecast, 2021-2031The global hypersonic technology industry analysis projects the market to have significant growth of CAGR 8.45% during the forecast period 2021-2031. United States is expected to dominate the global hypersonic technology market with an estimated share of 54.1% in 2031. China and Germany are the two most prominent countries having significant share in the hypersonic technology market.The global hypersonic technology market is gaining widespread importance owing to the increasing demand of hypersonic weapons, growing global defense spending and rising territorial conflicts. Moreover, the increasing focus on super fast intercontinental travel, development of counter-hypersonic systems, and advancements in Scramjet technology for hypersonic missiles are other important factors that may propel the market growth in the coming years.Scope of the Global Hypersonic Technology MarketThe purpose of the market analysis is to examine the global hypersonic technology market in terms of factors driving the market, trends, technological developments, and competitive benchmarking, among others.The report further takes into consideration the market dynamics and the competitive landscape of the key players operating in the market.Global Hypersonic Technology Market SegmentationThe report constitutes an extensive study of the global hypersonic technology industry.The report primarily focuses on providing market information on hypersonic technology covering various segments and countries.The global hypersonic technology market is segmented on the basis of end-user, type, launch-mode, and countries.While highlighting the key driving and restraining forces for this market, the report also provides a detailed study of the industry.The report analyzes different end-user that include military and space.The type segment is further segmented into hypersonic glide vehicles, hypersonic cruise missiles and space launch vehicles.The launch mode has been segmented into surface to surface, surface to air, air to air, and subsea to surface.The global hypersonic technology market is segregated into major countries, namely U.S., Russia, China, India, Australia, Japan, France, Germany, and Rest-of-the-World. Data for each of these countries is provided in the market study.Key Companies in the Global Hypersonic Technology IndustryThe key market players in the global hypersonic technology market include Aerojet Rocketdyne Holdings Inc., The Boeing Company, Brahmos Aerospace Pvt. Ltd., Lockheed Martin Corporation, Thales Group, General Dynamics Corporation, Northrop Grumman Corporation, Raytheon Company, Saab AB, Dynetics Inc., SpaceX, and L3 Harris Technologies Inc.Countries Covered• U.S.• Russia• China• India• Australia• Japan• France• Germany• Rest-of-the-WorldRead the full report: https://www.reportlinker.com/p06061844/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
The annual general meeting of shareholders of EfTEN Real Estate Fund III AS was held on 15 April 2021 in in the Radisson Blu Hotel Olümpia Conference Center (2nd floor, Tallinn, Liivalaia 33). A total of 160 shareholders attended the meeting representing 3 085 700 votes. This means 73,08 % of the total votes were represented. Of the participants, 37 shareholders representing 521,205 votes, i.e., 12.34% of all votes attached to the shares, cast their votes electronically before the meeting in accordance with the electronic voting procedure announced in the invitation to the meeting. The meeting therefore had a quorum. The decisions of the annual general meetoing were as follows: Approval of the annual report of EfTEN Real Estate Fund III AS for 2020With 3 085 462, i.e. 99,99 % votes in favour, the shareholders decided to approve the annual report of EfTEN Real Estate Fund III AS for the financial year 2020 in the form submitted to the meeting. Distribution of profitWith 3 085 462, i.e. 99,99 % votes in favour, the shareholders decided to approve the profit distribution proposal. The consolidated net profit of the 2020 financial year of the fund is 3.317 million euros. To distribute the undistributed profit as at 31 December 2020 in the total amount of 18,277,000 euros as follows: Transfers to the reserve capital: 166,000 euros;Profit to be distributed between the shareholders (net dividend): 2,798,000 euros (66.3 euro cents per share);Transfers to other reserves shall not be made and profit shall not be used for any other purposes. Amount of undistributed profit after transfers is 15,313,000 euros. The list of shareholders entitled to dividends shall be fixed on 04.06.2021 as at the end of the working day of the registrar of the settlement system of the fund’s securities. Therefore, the date of change in the rights attaching to shares (ex-date) is 03.06.2021. As of this date a person who acquired shares is not entitled to dividends for the 2020 financial year. Dividend shall be paid to the shareholders on 16.06.2021 by way of bank transfer to the shareholder’s bank account. Increase of the share capital and listing of new shares on the main list of the Nasdaq Tallinn Stock ExchangeWith 3 084 362, i.e. 99,96 % votes in favour, the shareholders decided to approve increase of the share capital and listing of new shares on the main list of the Nasdaq Tallinn Stock Exchange as follows:In order to continue the investment activities of the fund specified in the articles of association, to increase the share capital by 8,500,000 euros by way of issue of new shares as follows: 850,000 new shares with the nominal value of 10 euros are issued, as a result of which the new amount of the share capital is 50,725,350 euros. (The valid amount of share capital before the share capital increase is 42,225,350 euros);The shares must be paid for by a monetary contribution to bank account no. EE532200221061960175 of the fund in Swedbank;The shares are issued at a premium. The payment to be made for one share is its nominal value of 10 euros plus the minimum premium of 7.5 euros; the Supervisory Board may determine a higher premium than that at the latest by the commencement of subscription;The subscription of and payment for new shares take place in accordance with the procedure specified in the prospectus to be published before the commencement of the offer in the period from 14.05.2021 at 09:00 to 31.05.2021 at 16:00.The existing shareholders of the fund i.e., the persons who have been entered in the list of shareholders of the fund as of 29.04.2021 as at the end of the working day of Nasdaq CSD, have a pre-emptive right to subscribe for new shares in proportion to the sum of the nominal values of their shares within two weeks from the adoption of a resolution on increase of share capital. (The total number of shares of the fund before the increase of the share capital is 4,222,535);The offer of shares is deemed to be oversubscribed if there are more applications for subscription than for subscribing for 850,000 shares. In the case of oversubscription, the Supervisory Board of the fund decides on the distribution and cancellation of shares;If less than 850,000 shares have been subscribed, the Management Board of the fund has the right to extend the subscription period or to cancel the shares that are not subscribed for within the subscription period.The first financial year for which the shares to be issued grant the right to receive dividends is the 2021 financial year. In connection with the share capital increase, it was also decided to submit an application for the listing of all the fund’s new shares to be issued and for the admission thereof to trading on the main list of the Nasdaq Tallinn Stock Exchange and to authorise the Supervisory Board and Management Board of the fund to perform all acts and enter all contracts and agreements necessary to this end. The minutes of the general meeting shall be made available on the fund's website (https://eref.ee/investorile/uldkoosolekud/) not later than 7 days after the meeting. The video recording of the general meeting can be viewed via website of the fund (https://eref.ee/investorile/uldkoosolekud/) seven days, i.e. until 22.04.2021. Viljar ArakasMember of the Management BoardPhone 655 9515E-mail: firstname.lastname@example.org
Dublin, April 15, 2021 (GLOBE NEWSWIRE) -- The "Global Syringe Pump Market, By Type (Infusion Pump v/s Withdrawal Pump), By Application (ICU, Cardiac Surgery Units, Pediatric Units, Operating Theaters, Others), By End User (Hospitals & Clinics, Ambulatory Care Settings, Others), By Region, Forecast & Opportunities, 2027" report has been added to ResearchAndMarkets.com's offering. The Global Syringe Pump Market stood at USD19.60 billion in value terms in 2020 and is expected to grow at a CAGR of 7.21% and reach USD29.40 billion by 2026. The Global Syringe Pump Market is driven by the growing geriatric population suffering from various chronic diseases such as cancer, cardiovascular diseases, renal disorders, among others. This has drastically increased the number of patients and requirement for continuous monitoring of their health. This in turn is anticipated to positively impact the market growth during the next five years. Additionally, growing number of surgical procedures performed is also expected to foster the growth of the Global Syringe Pump Market. Furthermore, increasing investments and new product launches by the key vendors operating in the market is expected to create lucrative opportunities for the growth of the market through 2026.The Global Syringe Pump Market is segmented based on type, application, end-user, company, and region. Based on end-user, the market can be fragmented into hospitals & clinics, ambulatory care settings, and others. The hospitals and clinics segment accounted for 55.5% market share in 2020 and this is expected to further grow in the forecast period. This can be attributed to hospitals' considerable financial resources for buying innovative medical equipment for their patients. Additionally, large patient population coming to the hospitals coupled with the availability of skilled & trained professionals is further anticipated to fuel the growth of segment over the next few years.Regionally, the Global Syringe Pump Market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these, Asia-Pacific is expected to witness the highest growth in the overall syringe pump market owing to the improving healthcare infrastructure in the region. Additionally, growing geriatric population in the region which is suffering from different chronic diseases is further expected to spur the market growth through 2026.Major players operating in the Global Syringe Pump Market include Becton, Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., Fresenius Kabi, ICU Medical, Inc., Medtronic plc, Moog Inc., Terumo Corporation, Nipro Corporation, and Mindray Medical International Limited. The companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new service developments. Companies Mentioned Becton, Dickinson and CompanyB. Braun Melsungen AGBaxter International Inc.Fresenius KabiICU Medical, Inc.Medtronic plcMoog Inc.Terumo CorporationNipro CorporationMindray Medical International Limited Key Target Audience: Syringe pump manufacturers, suppliers, distributors, and other stakeholdersGovernment bodies such as regulating authorities and policy makersOrganizations, forums, and alliances related to syringe pumpsMarket research and consulting firms Years considered for this report: Historical Years: 2016-2019Base Year: 2020Estimated Year: 2021Forecast Period: 2022-2026 Report Scope:Global Syringe Pump Market, By Type: Infusion PumpWithdrawal Pump Global Syringe Pump Market, By Application: ICUCardiac Surgery UnitsPediatric UnitsOperating TheatersOthers Global Syringe Pump Market, By End-User: Hospitals & ClinicsAmbulatory Care SettingsOthers Global Syringe Pump Market, By Region: North AmericaUnited StatesCanadaMexicoEuropeGermanyFranceUnited KingdomItalySpainAsia-PacificChinaJapanIndiaSouth KoreaAustraliaMiddle East & AfricaSouth AfricaSaudi ArabiaUAEKuwaitSouth AmericaBrazilArgentinaColombia For more information about this report visit https://www.researchandmarkets.com/r/kf0no1 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The "Asia Pacific Electric Beds Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product; Application; End User and Country" report has been added to ResearchAndMarkets.com's offering.
Aspirants who have completed Class 10 exams with a minimum of 50% are eligible to apply for the post of Apprentice in the West Central Railway
At one of its increasingly regular presentations on Thursday, Netflix Spain unveiled seven new projects, including “If Only,” a Spanish adaptation of the Turkish original banned from shooting by Erdogan’s government. Where once Netflix would host its presentations early in the year and announce its ambitions for the next twelve months, the platform’s original Spanish […]
The "Skin Care Products Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.